Pulmonary Arterial Hypertension (PAH) Market – Industry Trends and Forecast to 2028
Global Pulmonary Arterial Hypertension Market, By Drug Type (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, and Others), Route of Administration (Oral, Inhaled, Intravenous, and Subcutaneous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028.
The pulmonary arterial hypertension (PAH) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the CAGR of 8.9% in the forecast period of 2021 to 2028. The growing number of clinical trials will help in escalating the growth of the pulmonary arterial hypertension (PAH)market.
Access Full 350 Pages PDF Report @
https://www.databridgemarketresearch.com/reports/global-pulmonary-arterial-hypertension-pah-market
**Segments**
- Based on drug class, the pulmonary arterial hypertension (PAH) market can be segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and others. Prostacyclin and prostacyclin analogs hold a significant market share due to their vasodilatory and anti-proliferative properties, helping in improving exercise capacity and overall quality of life for PAH patients. Endothelin receptor antagonists are also commonly prescribed as they target the endothelin pathway, which is crucial in the pathogenesis of PAH. Phosphodiesterase inhibitors, such as sildenafil and tadalafil, are used to increase levels of cyclic guanosine monophosphate (cGMP), leading to vasodilation in the pulmonary arteries. Soluble guanylate cyclase stimulators work by enhancing the nitric oxide pathway, providing an additional treatment option for PAH patients.
- Geographically, the PAH market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the market due to the high prevalence of PAH, well-established healthcare infrastructure, and increasing awareness about the disease. Europe follows closely behind, with a growing aging population contributing to the rise in PAH cases. The Asia-Pacific region is expected to witness significant growth in the coming years due to improving healthcare access, rising disposable incomes, and increasing investments in healthcare infrastructure.
- By distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominate the PAH market as they are the primary point of purchase for prescription medications. Retail pharmacies play a significant role in providing ongoing medication refills and patient education. The rise of online pharmacies has added a new dimension to the distribution of PAH drugs, offering convenience and accessibility to patients who may have difficulties visiting physical pharmacies.
**Market Players**
- Some of theIn the competitive landscape of the pulmonary arterial hypertension (PAH) market, there are several key players that are actively involved in research, development, manufacturing, and commercialization of PAH drugs. These market players are crucial in shaping the dynamics of the market by introducing innovative therapies, investing in clinical trials, and expanding their geographical presence. One of the prominent companies in the PAH market is Actelion Pharmaceuticals, a subsidiary of Johnson & Johnson, known for its endothelin receptor antagonist therapies. Actelion Pharmaceuticals has a strong portfolio of PAH drugs, including Tracleer (bosentan) and Opsumit (macitentan), which have been widely used in the treatment of PAH.
Another major player in the PAH market is United Therapeutics Corporation, specializing in prostacyclin analog therapies. United Therapeutics offers drugs such as Remodulin (treprostinil), Tyvaso (inhaled treprostinil), and Orenitram (oral treprostinil) for the management of PAH. The company has been focusing on developing innovative delivery systems for prostacyclin therapy to improve patient adherence and outcomes.
Bayer AG is also a significant player in the PAH market, with a strong presence in the phosphodiesterase inhibitor segment. Bayer's PAH portfolio includes Adempas (riociguat), a soluble guanylate cyclase stimulator indicated for PAH treatment. The company has been investing in clinical trials to explore the efficacy of riociguat in different PAH subtypes and combination therapies.
Gilead Sciences is another key player in the PAH market, known for its research in novel pathways for PAH treatment. The company's drug Letairis (ambrisentan), an endothelin receptor antagonist, has been a valuable addition to PAH treatment options. Gilead Sciences continues to invest in research and development to expand its PAH portfolio and address unmet medical needs in the market.
**Global Pulmonary Arterial Hypertension Market, By Drug Type (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, and Others), Route of Administration (Oral, Inhaled, Intravenous, and Subcutaneous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
- The global pulmonary arterial hypertension (PAH) market is experiencing significant growth and is segmented based on drug type, route of administration, distribution channel, and geography. Endothelin receptor antagonists (ERAs), including drugs like ambrisentan and bosentan, play a crucial role in managing PAH by targeting the endothelin pathway. Phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil and tadalafil are
Pulmonary Arterial Hypertension (PAH) Key Benefits over Global Competitors:
- The report provides a qualitative and quantitative analysis of the Pulmonary Arterial Hypertension (PAH) Market trends, forecasts, and market size to determine new opportunities.
- Porter’s Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.
- Top impacting factors & major investment pockets are highlighted in the research.
- The major countries in each region are analyzed and their revenue contribution is mentioned.
- The market player positioning segment provides an understanding of the current position of the market players active in the Personal Care Ingredients
Table of Contents: Pulmonary Arterial Hypertension (PAH) Market
1 Introduction
2 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation
3 Executive Summary
4 Premium Insight
5 Market Overview
6 Pulmonary Arterial Hypertension (PAH) Market, by Product Type
7 Pulmonary Arterial Hypertension (PAH) Market, by Modality
8 Pulmonary Arterial Hypertension (PAH) Market, by Type
9 Pulmonary Arterial Hypertension (PAH) Market, by Mode
10 Pulmonary Arterial Hypertension (PAH) Market, by End User
12 Pulmonary Arterial Hypertension (PAH) Market, by Geography
12 Pulmonary Arterial Hypertension (PAH) Market, Company Landscape
13 Swot Analysis
14 Company Profiles
Critical Insights Related to the Pulmonary Arterial Hypertension (PAH) Included in the Report:
- Exclusive graphics and Illustrative Porter’s Five Forces analysis of some of the leading companies in this market
- Value chain analysis of prominent players in the market
- Current trends influencing the dynamics of this market across various geographies
- Recent mergers, acquisitions, collaborations, and partnerships
- Revenue growth of this industry over the forecast period
- Marketing strategy study and growth trends
- Growth-driven factor analysis
- Emerging recess segments and region-wise market
- An empirical evaluation of the curve of this market
- Ancient, Present, and Probable scope of the market from both prospect value and volume
Browse Trending Reports:
Smart Fertilizers Market
Pesticide Products Market
Isobutyryl Coa Dehydrogenase Deficiency Treatment Market
Botanical Native Pesticides Market
Wide Body Aircraft Market
Gps Positioning Systems Market
Fragrance Oil Market
Electric 9 Wheeler Market
Commercial Refrigeration And Air Conditioning Positive Displacement Compressor Market
Investment Casting Market
Intercontinental Ballistic Missile Market
Mediastinal Mass Treatment Market
Pneumothorax Infection Treatment Market
Biofuel Lubricity Improvers Market
Cancer Treatment Market
Diesel Exhaust Fluid Market
Polyethylene Terephthalate Pet Reclosable Films Market
Sliding Sleeves Market
Paperboard Beverage Packaging Market
Livestock Monitoring Market
Hemoglobin Meter Market
Microporous Hygiene Breathable Films Market
Canned Meat Market
Pityriasis Rubra Pilaris Treatment Market
Fluorocarbon Based Vacuum Grease Market
Micro Positron Emission Tomography Pet Systems Market
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek